Fig. 5

Determination of PNSC928 cytotoxicity and evaluation of PNSC928 effects on the expression levels of CtBP2/p300/NF-κB target genes. (A-E) Cell viability assessment. Five cell lines, including MPAEpiC (A), RAW264.7 (B), FL83B (C), TKPTS (D), and HL-1 (E) were treated with varying concentrations of PNSC928 (0, 11.8, 23.6, and 46.7 µM). Cell viability was assessed every 24 h for 5 days. (F-I) Effects of PNSC928 on gene expression levels. The RAW264.7 cells were co-treated with LPS and PNSC928 (23.6 and 47.2 µM) for a duration of 6 h. Subsequently, RNA isolation and RT-qPCR analysis were performed to quantify mRNA levels of various genes. (F) The mRNA levels of IL-1B, IL-6, IL-15, IL-18, TNFA, and IFNG. (G) The mRNA levels of CDH1, CDKN1A, CDKN2A, CHRD, PAX6, and BAX. (H) The mRNA levels of NOD2, CCL2, CXCL10, CXCL12, MMP1, and STAT1 mRNA levels, (I) The mRNA levels of MIP2, CCR5, GM-CSF, COX2, and iNOS. n = 3 for each experiment. ns: no significant difference. **P < 0.01; ***P < 0.001